This article was originally published in Start Up
The founders of Sequential Inc. think breast and other cancers may be the outcome of "sequential pathogenesis," the process of an abnormal macrophage causing other cells to become sick. The company has in-licensed a compound it believes will be beneficial for pre-treating breast cancer patients scheduled for surgery (a growing trend called neoadjuvant therapy). Meanwhile, Sequential is pursuing targets that may be involved in sequential pathogenesis, and developing a compound of its own.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.